| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/26/2011 | CA2433186C Delayed release pharmaceutical formulations |
| 04/26/2011 | CA2428785C Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| 04/26/2011 | CA2424565C Novel crystalline forms of a factor xa inhibitor |
| 04/26/2011 | CA2408838C Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 04/26/2011 | CA2388656C Use of biodegradable microspheres that release an anticancer agent for treating gliobastoma |
| 04/26/2011 | CA2377529C Injectable hyaluronate-sulfated polysaccharide conjugates |
| 04/26/2011 | CA2371109C Improved pharmaceutical formulations |
| 04/26/2011 | CA2359945C Inhibitors of crystallization in a solid dispersion |
| 04/26/2011 | CA2341358C Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| 04/26/2011 | CA2309602C Methods and compositions for enhancing immune response and for the production of in vitro mabs |
| 04/26/2011 | CA2298934C Vectors derived from antibodies for transferring substances into cells |
| 04/26/2011 | CA2289009C Multivalent vaccine composition with mixed carrier |
| 04/26/2011 | CA2264012C Compositions and methods for polynucleotide delivery |
| 04/21/2011 | WO2011047378A1 Methods and compositions for novel liquid crystal delivery systems |
| 04/21/2011 | WO2011047277A2 Release of agents from cells |
| 04/21/2011 | WO2011047051A2 Polymeric systems for the delivery of anticancer agents |
| 04/21/2011 | WO2011046199A1 Method for producing reduced coenzyme q10, method for stabilizing same, and composition comprising same |
| 04/21/2011 | WO2011045934A1 Method for producing reduced coenzyme q10, method for stabilizing same, and composition comprising same |
| 04/21/2011 | WO2011045809A1 Liposomal amphotericin formulation comprising cholesterol for treating fungal infections |
| 04/21/2011 | WO2011045682A2 Active agent containing polymer network delivery composition and articles using the same |
| 04/21/2011 | WO2011045681A2 Carbohydrate entrapped active agent delivery composition and articles using the same |
| 04/21/2011 | WO2011045668A1 Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof |
| 04/21/2011 | WO2011045550A1 Method for preparing a recyclable polyamide powder |
| 04/21/2011 | WO2011045296A1 Delivery agent |
| 04/21/2011 | WO2011044824A1 Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treament of cancer thereof |
| 04/21/2011 | WO2011044701A1 Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods |
| 04/21/2011 | WO2011044671A1 Porphyrin nanovesicles |
| 04/21/2011 | WO2011026132A3 Methods and compositions for the inhibition of transplant rejection |
| 04/21/2011 | WO2011024110A3 Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| 04/21/2011 | WO2010144755A3 Compositions and methods for delivery of materials |
| 04/21/2011 | WO2010138519A9 Use of adsorbent carbon microspheres for the treatment of pruritus |
| 04/21/2011 | WO2010137888A3 Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same |
| 04/21/2011 | WO2010135527A3 Elastin for soft tissue augmentation |
| 04/21/2011 | WO2010132474A3 Stable elastomeric negative acoustic contrast particles and their use in acoustic radiation fields |
| 04/21/2011 | WO2010132471A3 Synthesis of stable elastomeric negative acoustic contrast particles |
| 04/21/2011 | WO2010129819A3 Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
| 04/21/2011 | WO2010123945A3 Silk fibroin hydrogels and uses thereof |
| 04/21/2011 | US20110092677 Modified transferin-antibody fusion proteins |
| 04/21/2011 | US20110092669 Synthesis of cyclosporin analogs |
| 04/21/2011 | US20110092605 Encapsulation |
| 04/21/2011 | US20110092603 Composition to enhance the bioavailability of curcumin |
| 04/21/2011 | US20110092598 Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof |
| 04/21/2011 | US20110092471 Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 04/21/2011 | US20110091577 Drug release coatings on calcuim phosphate and uses thereof |
| 04/21/2011 | US20110091562 Nanogels for cellular delivery of therapeutics |
| 04/21/2011 | US20110091560 Compositions of nanoparticles and methods of making the same |
| 04/21/2011 | US20110091546 Composition for rapid disintegrating tablet in oral cavity |
| 04/21/2011 | US20110091541 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 04/21/2011 | US20110091525 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 04/21/2011 | US20110091522 Edible chew pill jacket |
| 04/21/2011 | US20110091488 Water-swellable polymers |
| 04/21/2011 | US20110091415 Hydroxyethyl Starch-Containing Polypeptide Compositions |
| 04/21/2011 | US20110091406 Composition and method for protecting labile active components during high temperature drying |
| 04/21/2011 | US20110091399 Use of organo-modified siloxane block copolymers for producing cosmetic or pharmaceutical compositions |
| 04/21/2011 | CA2777629A1 Compounds having peptides conjugated to bone targeting moieties and methods of making and using thereof |
| 04/21/2011 | CA2777628A1 Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods |
| 04/21/2011 | CA2777397A1 Polymeric systems for the delivery of anticancer agents |
| 04/21/2011 | CA2776796A1 Porphyrin nanovesicles |
| 04/20/2011 | EP2311973A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/20/2011 | EP2311956A1 Methods for making APO-2 ligand using divalent metal ions |
| 04/20/2011 | EP2311895A1 Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| 04/20/2011 | EP2311883A1 Hydrogel |
| 04/20/2011 | EP2311882A1 Reducing the immunogenicity of fusion proteins |
| 04/20/2011 | EP2311881A2 Cripto binding molecules |
| 04/20/2011 | EP2311880A2 Cripto binding molecules |
| 04/20/2011 | EP2311879A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311878A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311877A2 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311854A1 Mutated pseudomonas exotoxins with reduced antigenicity |
| 04/20/2011 | EP2311500A1 Labeling targeting agents with gallium-68 and gallium-67 |
| 04/20/2011 | EP2311498A1 External preparation comprising fatty acid salt or benzoic acid salt of basic pharmacologically active component, and method for production thereof |
| 04/20/2011 | EP2311494A1 Histone modification inhibitor specific to target gene |
| 04/20/2011 | EP2311492A1 Antibody-containing stabilized preparations |
| 04/20/2011 | EP2311491A1 Composition comprising an antibody against macrophage colony-stimulating factor (M-CSF) and a chelating agent |
| 04/20/2011 | EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment |
| 04/20/2011 | EP2311489A2 Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
| 04/20/2011 | EP2311465A1 Remedies for diseases to be applied to eye |
| 04/20/2011 | EP2311456A1 Wound and mucous membrane antiseptic based on bispyridiniumalkanes |
| 04/20/2011 | EP2311444A1 Method for preparing a stabilised menthol emulsion |
| 04/20/2011 | EP2311442A1 Multiparticulate modified release composition |
| 04/20/2011 | EP2311440A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 04/20/2011 | EP2311438A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/20/2011 | EP2311437A1 Stabilised compositions of factor VII polypeptides |
| 04/20/2011 | EP2311436A1 Stabilized protein crystals, formulations containing them and methods of making them |
| 04/20/2011 | EP2311435A1 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
| 04/20/2011 | EP2311431A1 Short duration depot formulations |
| 04/20/2011 | EP2310459A2 Improved cross-linked compositions |
| 04/20/2011 | EP2310053A1 Pharmaceutical compositions comprising a complex of aminocyclohexane derivatives and cyclodextrin |
| 04/20/2011 | EP2309997A2 Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| 04/20/2011 | EP2309991A2 Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| 04/20/2011 | EP2309990A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 04/20/2011 | EP2309989A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 04/20/2011 | EP2309986A1 Biodegradable impact-modified polymer compositions |
| 04/20/2011 | EP2309985A2 Pharmaceutical composition |
| 04/20/2011 | EP2309982A2 Controlled release copolymer formulation with improved release kinetics |
| 04/20/2011 | EP2309980A1 Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| 04/20/2011 | EP2309979A1 Delivery of dry formulations of octreotide |
| 04/20/2011 | EP2309969A2 Delivery product for topical compositions |
| 04/20/2011 | EP2077293B1 Block copolymer for drug conjugates and their pharmaceutical compositions |